The burden of severe pneumonia in terms of morbidity and mortality is unknown in India especially at sub-national level. In this context, we aimed to estimate the number of severe pneumonia episodes, pneumococcal pneumonia episodes and pneumonia deaths in children younger than 5 years in 2010. We adapted and parameterized a mathematical model based on the epidemiological concept of potential impact fraction developed CHERG for this analysis. The key parameters that determine the distribution of severe pneumonia episode across Indian states were state-specific under-5 population, state-specific prevalence of selected definite pneumonia risk factors and meta-estimates of relative risks for each of these risk factors. We applied the incidence estimates and attributable fraction of risk factors to population estimates for 2010 of each Indian state. We then estimated the number of pneumococcal pneumonia cases by applying the vaccine probe methodology to an existing trial. We estimated mortality due to severe pneumonia and pneumococcal pneumonia by combining incidence estimates with case fatality ratios from multi-centric hospital-based studies. Our results suggest that in 2010, 3.6 million (3.3–3.9 million) episodes of severe pneumonia and 0.35 million (0.31–0.40 million) all cause pneumonia deaths occurred in children younger than 5 years in India. The states that merit special mention include Uttar Pradesh where 18.1% children reside but contribute 24% of pneumonia cases and 26% pneumonia deaths, Bihar (11.3% children, 16% cases, 22% deaths) Madhya Pradesh (6.6% children, 9% cases, 12% deaths), and Rajasthan (6.6% children, 8% cases, 11% deaths). Further, we estimated that 0.56 million (0.49–0.64 million) severe episodes of pneumococcal pneumonia and 105 thousand (92–119 thousand) pneumococcal deaths occurred in India. The top contributors to India’s pneumococcal pneumonia burden were Uttar Pradesh, Bihar, Madhya Pradesh and Rajasthan in that order. Our results highlight the need to improve access to care and increase coverage and equity of pneumonia preventing vaccines in states with high pneumonia burden.
Citation: Farooqui H, Jit M, Heymann DL, Zodpey S (2015) Burden of Severe Pneumonia, Pneumococcal Pneumonia and Pneumonia Deaths in Indian States: Modelling Based Estimates. PLoS ONE 10(6): e0129191. doi:10.1371/journal.pone.0129191
Academic Editor: Philip C. Hill, University of Otago, NEW ZEALAND
Received: October 13, 2014; Accepted: May 7, 2015; Published: June 18, 2015
Copyright: © 2015 Farooqui et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by a Wellcome Trust Capacity Strengthening Strategic Award to the Public Health Foundation of India and a consortium of UK universities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
Pneumonia is one of the most common causes of morbidity and mortality in children younger than 5 years in India. The Millennium Development Goal (MDG) 4, which focuses on reduction of under-five mortality, has generated significant momentum for accurate assessment of cause-specific under five morbidity and mortality. In 2004, global estimates on incidence of clinical pneumonia in children younger than 5 years were first generated and published by Rudan et al.. For developing countries, these estimates suggested that median incidence was 0.28 episodes per child-year, with an interquartile range 0.21–0.71 episodes per child-year. In 2008, the Child Health Epidemiology Reference Group (CHERG) established by the World Health Organization (WHO) revised the estimates of childhood pneumonia morbidity and mortality and also identified lack of exclusive breastfeeding, under-nutrition, indoor air pollution, low birth weight, crowding and lack of measles immunization as leading risk factors contributing to pneumonia incidence. In addition, they mentioned that five countries where 44% of the world’s children aged less than 5 years live (India, China, Pakistan, Bangladesh, Indonesia, Nigeria) contribute more than half of the new pneumonia cases annually. For India, they predicted around 43 million pneumonia cases (23% of the world’s total) and estimated an incidence of 0.37 episodes per child-year for clinical pneumonia.
One of the major contributors to the pneumonia burden is Streptococcus pneumonia; others include Hemophilus influenzae, Respiratory syncitical virus and Influenza. However, the estimation of pneumococcal pneumonia among clinical pneumonia episodes has remained a challenge in developing nations due to lack of laboratory diagnostic support and surveillance systems to capture the etiologic agents for pneumonia. Also, the majority of pneumococcal pneumonia infections are not bacteraemic, and hence not identifiable through cultures of sterile site body fluids. To address these limitations and to estimate the true burden of vaccine preventable diseases, the vaccine probe approach has emerged as a promising alternative. In this approach, the burden of pneumonia prevented by a specific vaccine is presumed to be a minimum estimate of the burden of pneumonia due to the organism against which the vaccine is directed. Using this approach, O’Brien et al. estimated burden of disease caused by Streptococcus pneumoniae in children younger than 5 years by applying efficacy estimates derived from pneumococcal vaccine trials to WHO country-specific estimates of all-cause pneumonia cases and deaths.. In 2013, Walker et al. published the first ever global estimates of the contribution of other vaccine-preventable causes (Streptococcus pneumoniae, Haemophilus influenzae and influenza) of severe clinical pneumonia cases and deaths using the same approach.
However, one of the limitations of the above global pneumonia estimates[3–5, 7] was focus on WHO regions instead of the member states. This limitation has been addressed partly by Rudan et al. in their revised estimates on incidence, severe morbidity, mortality, underlying risk factors and causative pathogens of clinical pneumonia for 192 countries. However, for a large country like India, estimates of pneumonia burden at sub-national (states) level are still not available. It is recognized that for India, which accounts for 23% of the global pneumonia burden and 36% of the WHO regional burden, national estimates may hide significant sub-national disparities[1, 4]. For example, a large nationally representative survey has reported that in 2005, pneumonia contributed 13.5% of deaths in children age 1–59 months. However, it was observed that the girls in central India had a five-times higher mortality rate (per 1000 live births) from pneumonia than did boys in south India. Further, the lack of reliable estimates of pneumonia burden in terms of etiology has led to under-utilization of existing preventive interventions. In this context, we have generated Indian state-specific estimates for burden of severe pneumonia, pneumococcal pneumonia and pneumonia deaths to provide guidance for pneumonia control program.
To estimate the number of new episodes of severe pneumonia for each Indian state we have adapted and parameterized a model that was originally developed and validated by the CHERG group using Microsoft Excel. The model is based on the epidemiological concept of potential impact fraction as follows: where Ne/cy is the number of new episodes of severe pneumonia per year in each Indian state, Pop< 5yrs is the population of children less than 5 years in each state, IncInd is the estimated incidence of severe clinical pneumonia at the all-India level, PrevRFn is the prevalence of exposure to n-th risk factor among under-fives in the Indian state, PrevRFnInd is the prevalence of exposure to n-th risk factor among under-fives at all India level and RRRFn is the relative risk for developing pneumonia associated with the n-th risk factor.
The methods and model used to estimate and distribute the annual number of severe pneumonia episodes and pneumococcal pneumonia episodes has been explained in detail in a subsequent section. In addition, the parameter values and associated data sources are also explained.
The total number of severe pneumonia episodes in children age less than 1 year was estimated by multiplying the number of all children age less than 1 year living in each Indian state in year 2010 by an incidence of 0.068 severe pneumonia episodes per child-year.
The data on population for each Indian state for year 2010 (with one-year age interval) was collected from Census of India whereas the incidence of severe pneumonia in children age less than 1 year was estimated through meta-analysis of selected population based cohort studies[12–14] that have used WHO-defined chest-radiography-positive pneumonia in case definition. However, the incidence rate of severe pneumonia for other age intervals (1–2 years, 2–3 years, 3–4 years and 4–5 years) was estimated through fitting data from hospital based multi-centric surveillance study[15, 16] to an appropriate distribution (gamma). The incidence estimates were adjusted to account for access to health services. The information regarding access to health services was imputed from District Level Household and Facility Survey (DLHS-3) which is a nationwide survey covering 601 districts from 34 states and union territories of India. Finally, the total number of severe pneumonia episodes in children age less than 5 years was calculated as sum total of all severe pneumonia episodes across all age intervals, which was estimated through repeating the process, mentioned above for other age intervals (1–2 years, 2–3 years, 3–4 years and 4–5 years) (S1 File).
The total number of severe pneumonia episodes in children age less than 5 years estimated from step 1 were then distributed into state-specific estimates on the basis of three parameters (a) state-specific under-5 population, (b) state-specific prevalence of selected definite pneumonia risk factors (prevalence of malnutrition (weight–for–age z<–2), low birth weight (≤2500 g), non–exclusive breastfeeding (in the first 4 months) and solid fuel use (‘yes’) and (c) meta-estimates of relative risks for each of these risk factors.
The information on prevalence of the definite risk factors was available through National Family Health Survey-3 (NFHS) . The NFHS surveys are conducted every 5–6 years under the stewardship of the Ministry of Health and Family Welfare (MOHFW), Government of India. The survey is based on a sample of households that is representative at the national and state levels and provides trend data on key indicators. The key risk factors included in the model—i.e. prevalence of malnutrition, low birth weight, non–exclusive breastfeeding and solid fuel use—have consistently shown significant effects in multivariate study designs [4, 7, 8, 19, 20]. The meta-estimates of relative risks (RR) for the selected definite risk factors were taken from an earlier study as follows: malnutrition-(RR-1.8), low birth weight (RR-1.4), non-exclusive breastfeeding (RR-1.9) and indoor air pollution (RR-1.8).
The total number of pneumococcal pneumonia episodes was estimated by applying attributable proportion of 36.51% for Streptococcus pneumoniae to all-cause severe pneumonia episodes in children age less than 5 years across Indian states estimated from step 2.
To determine the proportions of pneumonia cases attributable to Streptococcus pneumoniae, we relied on pneumococcal conjugate vaccine efficacy trial conducted in Philippines, which was the only trial conducted in Asia. This trial was conducted in 2000 prior to introduction of Hib in Philippines (2010), so prevalence of non-pneumococcal causes of pneumonia was likely to be similar. The efficacy of the vaccine against a relevant definition of pneumonia was adjusted to account for vaccine serotype coverage and efficacy against pneumococcal pneumonia. We used the conjugate vaccine efficacy against WHO-defined chest-radiography-positive pneumonia as a measure of the proportion of pneumonia cases attributable to S pneumoniae. The Philippines trial reported 19.8% efficacy against radiologic pneumonia ((95% CI: -8.8, 40.8) in children age less than 1 year. The 11 serotypes contained in the vaccine (1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) were estimated to account for 65.33% of Invasive Pneumococcal Disease (IPD) in the India based on a multi-centric surveillance study. With vaccine efficacy against vaccine-type pneumococcal disease assumed to be 83%, we estimated that 23.8% (= 19.8/83) of radiologic pneumonia cases are due to the 11-pneumococcal serotypes in the vaccine and 36.51% due to any pneumococcal serotypes. Hence, radiologic pneumonia cases attributable to S Pneumoniae were 36.51%.
To estimate and distribute all-cause pneumonia mortality and pneumococcal pneumonia mortality in children age less than 5 years, the case fatality rate of 1.95% in severe pneumonia was applied to all-cause severe pneumonia episodes estimated in step 2 and the case fatality rate of 16.7% in pneumococcal pneumonia was applied to pneumococcal pneumonia episodes estimated in step 3. These mortality estimates in children age less than 5 years were estimated from multi-centric hospital based studies[14, 24] and were scaled across Indian states in accordance with pneumonia mortality rates reported by Million Death Study for India. The parameterized model is provided as supplementary material (S1 File).
We estimated that in year 2010, 3.6 million (3.3–3.9 million) episodes of severe pneumonia and 0.35 million (0.3–0.4 million) pneumonia deaths (all-cause) occurred in children younger than 5 years in India (Table 1). The estimated incidence of severe pneumonia was 30.7 (95% CI, 28.1–33.5) per 1000 children per year in those less than 5 years of age, and 87.3 (95% CI, 80.1–95.2) in children aged less than 1 year.
Further, we conducted a disaggregated state-specific analysis for 29 states of India. The estimated annual severe pneumonia incidence varied greatly from one state to another: 7.2 episodes (95% CI, 6.6–7.8) per 1000 children in Manipur to 50.3 episodes (95% CI, 46.2–54.9) per 1000 children in Jharkhand. We observed that southern states (Kerala, Tamil Nadu) and northeastern states (Sikkim, Manipur) have significantly lower incidence and mortality from severe pneumonia as compared to rest of the India (Table 1). In age-stratified analysis, we observed that severe pneumonia related morbidity followed a skewed distribution: highest morbidity in the 0–1 year age group (51%) followed by the 1–2 year age group (22%) (S1 File).
We estimated that Jharkhand had the highest incidence of severe pneumonia but Uttar Pradesh (UP) had the highest number of cases because of a large population of children younger than 5 years. The states that merit special mention include Uttar Pradesh (UP) from central India where 18.1% children reside but contribute 24% of pneumonia cases, Bihar (eastern India, 11.3% children, 16% of cases), Madhya Pradesh (MP) (central India, 6.6% children, 9% of cases), and Rajasthan (northern India, 6.6% children, 8% of cases). We observed that the distribution of pneumonia mortality among across Indian states followed a trend similar to that of severe pneumonia (Fig 1A). Of 3.6 million episodes of severe pneumonia and 0.35 million deaths that occurred in children aged less than 5 years in India, the top five contributors were UP (24% of cases and 26% of deaths), followed by Bihar (16% of cases, 22% of deaths), MP (9% of cases, 12% of deaths), Rajasthan (8% of cases, 11% of deaths) and Jharkhand (5% of cases, 6% of deaths) as top five contributors (Fig 1B).
(A) Number of severe pneumonia episodes in children aged 0–59 months (B) Number of pneumonia deaths in children aged 0–59 months.
Further, we estimated that in year 2010, 0.56 million (0.49–0.64 million) severe pneumococcal pneumonia episodes and 105 thousand (92–119 thousand) pneumococcal pneumonia deaths had occurred in children younger than 5 years of age in India. The annual incidence of severe pneumococcal pneumonia in India was estimated to be 4.8 episodes (95% CI, 4.2–5.5) per 1000 children younger than 5 years. The top five contributors to India’s pneumococcal pneumonia burden in terms of number of cases and deaths were again Uttar Pradesh (1,33,167 cases 27, 785 deaths), Bihar (91,578 cases, 23,202 deaths) Madhya Pradesh (52,250 cases, 13,043 deaths), Rajasthan (43,911 cases, 11,889 thousand death) and Jharkhand (28,969 cases, 6296 deaths) (Fig 2). The incidence estimate for pneumococcal pneumonia episodes was highest in Jharkhand (7.9 episodes per 1000 child) and lowest in Manipur (1.1 episodes per 1000 child)
Bubble size indicates the number of pneumococcal pneumonia deaths.
It is recognized that severe pneumonia has a higher proportion of cases attributable to S. pneumonia, and leads to more severe outcomes. It is thus preferred for use in estimating the burden of pneumonia. We also observed that the burden of clinical pneumonia was significantly higher than severe pneumonia: of all clinical pneumonia cases, 21.2% (95% CI, 18.0–24.9) were classified as severe, and we estimated that the proportion of pneumococcal pneumonia among all severe pneumonia was 15.8% whereas pneumococcal pneumonia deaths among all cause pneumonia deaths were 29.5%. Finally, we estimated a case fatality rate in severe pneumonia of 9.96%, comparable to case fatality rates of 10.8% reported in earlier estimates.
It is recognized that interpretation of country level pneumonia estimates is challenging, especially for large countries like India and China because clinical pneumonia incidence, access to care and childhood mortality vary substantially within the country. We have attempted to address this limitation by generating state specific estimates on burden of severe pneumonia, pneumococcal pneumonia and pneumonia related mortality. Our pneumonia estimates are based on the epidemiological concept of potential fraction of key risk factors for pneumonia. Hence, our estimates capture the impact of varying levels of prevalence of key risk factors across different states in India. Also, varying degree of access to care across states has been captured in the model (S1 File). Further, the pneumococcal pneumonia estimates are based on applying a vaccine probe approach to an existing trial (see methods). The primary reason for adopting this approach is recognition of the fact that until new diagnostic methods become available, models using the vaccine probe approach are reliable in estimating cause-specific pneumonia disease burden.
To check the consistency and plausibility of severe pneumonia estimates generated by our model we compared them against other published estimates for India. We estimated 3.6 million episodes of severe pneumonia in children younger than 5 years for the year 2010, which was similar to the estimate of 4.0 million episodes reported by CHERG for India . Further, our model predicted severe pneumonia incidence of 30.7 episodes per 1000 child per-year, which was similar to incidence reported by the CHERG (32.0 episodes per 1000 child per-year) . The methodological and modelling approach adopted by CHERG group and our group were essentially the same. They key difference was in the parameter values as explained in methodology section. We also checked the plausibility of state-specific estimates for pneumococcal pneumonia. Our model predicted a pneumococcal disease incidence of 4.4 (95% CI, 3.8–5.0) cases per 1000 in children younger than 5 years of age. This was similar to an invasive pneumococcal disease rate of 4.5 cases per 1000 children reported from neighboring geographical area of Bangladesh by a population-based, active-surveillance, and active-case detection study.
In the state-specific analysis we observed that in general, the states having a high prevalence of pneumonia risk factors and poor access to health services had a higher burden of pneumonia cases and deaths[17, 18]. This is consistent with reports of successive national health surveys highlighting that poor health infrastructure and health services, poor percentage of institutional deliveries, low immunization coverage rates and other health system weaknesses have led to high pneumonia burden in these states[17, 18, 20, 26] especially UP, Bihar, MP and Rajasthan.
With reference to the contribution of pneumococcal pneumonia to severe pneumonia episodes, we estimated a pneumococcal pneumonia contribution of 15.8% to all-cause severe pneumonia, as compared to 18.4% reported by Rudan et al. [7, 8]. This difference possibly occurred because of differing methodological approaches for the estimation of attributable proportion. Within the framework of the vaccine probe approach, other researchers (Rudan et al, O’ Brien et al and Walker et al.) have used the conjugate vaccine efficacy against WHO-defined clinical pneumonia as a measure of the proportion of pneumonia cases attributable to S. pneumoniae. Our group has used the conjugate vaccine efficacy against WHO-defined chest-radiography-positive pneumonia as a measure of the proportion of pneumonia cases attributable to S. pneumonia, with adjustment for vaccine serotype distribution across the India. Finally, our estimate of contribution of S. pneumoniae mortality (29.5%) to all cause pneumonia mortality is similar to that estimated by other researchers (32.9%)[7, 8].
Our national and state-specific estimates were generated using the same statistical model based on the epidemiological concept of potential impact fraction. Hence, the comparability of our national level estimates with other studies provides reasonable confidence that state level estimates for severe pneumonia, pneumococcal pneumonia and pneumonia deaths are also robust. Furthermore, we are reasonably confident of our age-specific estimates of pneumonia morbidity and mortality. We observed that the distribution of pneumonia cases and deaths followed a right skewed distribution with the highest burden in the youngest age group, and it then decreases in older groups. Our findings are consistent with community based longitudinal cohorts and multi-centric surveillance studies from India reporting skewed distribution of pneumonia burden [12, 13, 22, 24, 27, 28].
One of methodological limitations of our model is that it does not necessarily assume that the risk factors are independent, because we applied a meta-estimate of relative risks derived primarily from the studies of multivariate design. Also, our child population estimates were for the year 2010, the prevalence of exposures to risk factors was for the years 2006–07, and the childhood pneumonia estimates were based on studies conducted between 2007–2010. Hence, the estimates for pneumonia may be an over-estimate because the prevalence of risk factors has decreased, and access to care has increased over the last decade[7, 8]. Another potential factor that could contribute to an overestimate is availability of pneumococcal conjugate vaccines (PCV) in India. Although the PCV is available in the private sector since 2008, the coverage is negligible (<1% in major states) and the vaccine has not yet been introduced into the universal immunization programme.
Another potential limitation of our study is the fact that other researchers assume that individual estimates of cause-specific etiologies for pneumonia add up to a total estimated pneumonia envelope because we have not attempted to do the same[7, 8]. The focus of our study was to offer insights into the actual distribution of severe pneumonia, pneumococcal pneumonia and pneumonia deaths to inform policy on pneumonia prevention and control. It is recognized that pneumonia related morbidity and mortality are good indicators of the economic burden of pneumonia, since households incur significant healthcare cost and productivity losses as a result of hospitalization due to pneumonia. Information on the burden of severe pneumonia in different age groups and across all states in India would be helpful in designing and delivering targeted interventions to specific populations.
Finally, the use of conjugate vaccines against pneumonia, especially Streptococcus pneumonia and Hemophilius influenza, appears to be warranted for the prevention pneumonia morbidity and mortality in children younger than 5 years. In India, state specific estimates of the pneumonia burden and mortality could be used to identify states where vaccination and other interventions are required; and age specific estimates could help identify at what age vaccines should be used to achieve highest impact . Adopting this practice would accelerate progress towards MDG4, and would also contribute to a reduction in regional disparities of child health indicators.
S1 File. Parameterized Microsoft Excel based model.
This work was supported by a Wellcome Trust Capacity Strengthening Strategic Award to the Public Health Foundation of India and a consortium of UK universities.
Conceived and designed the experiments: HHF MJ. Performed the experiments: HHF MJ. Analyzed the data: HHF MJ DLH SZ. Contributed reagents/materials/analysis tools: HHF MJ DLH SZ. Wrote the paper: HHF MJ DLH SZ. Read and approved manuscript: HHF MJ DLH SZ.
- 1. Million Death Study C, Bassani DG, Kumar R, Awasthi S, Morris SK, Paul VK, et al. Causes of neonatal and child mortality in India: a nationally representative mortality survey. Lancet. 2010;376(9755):1853–60. doi: 10.1016/S0140-6736(10)61461-4 pmid:21075444; PubMed Central PMCID: PMC3042727.
- 2. UN Web Services Section, Information DoP. United Nations Millenium Development Goals 2014 [cited 2014 8 April]. Available from: http://www.un.org/millenniumgoals/.
- 3. Rudan I, Tomaskovic L, Boschi–Pinto C, H. C. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 2004;(82):895–903. pmid:15654403
- 4. Rudan I, Boschi-Pinto C, Biloglav Z, Mulholland K, Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;86(5):408–16. Epub 2008/06/12. pmid:18545744; PubMed Central PMCID: PMC2647437. doi: 10.2471/blt.07.048769
- 5. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, McCall N, et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet. 2009;374(9693):893–902. Epub 2009/09/15. doi: 10.1016/S0140-6736(09)61204-6 pmid:19748398.
- 6. Kim. M. Use of vaccine trials to estimate burden of disease. J Health Popul Nutr 2004;(22):257–67. pmid:15609778
- 7. Walker CL, Rudan I, Liu L, Nair H, Theodoratou E, Bhutta ZA, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405–16. Epub 2013/04/16. doi: 10.1016/S0140-6736(13)60222-6 pmid:23582727.
- 8. Rudan I, O'Brien KL, Nair H, Liu L, Theodoratou E, Qazi S, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. Journal of global health. 2013;3(1):10401. Epub 2013/07/05. doi: 10.7189/jogh.03.010401 pmid:23826505; PubMed Central PMCID: PMC3700032.
- 9. Liu L, Johnson HL, Cousens S, Perin J, Scott S, Lawn JE, et al. Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000. Lancet. 2012;379(9832):2151–61. Epub 2012/05/15. doi: 10.1016/S0140-6736(12)60560-1 pmid:22579125.
- 10. Rothman K, Greenland S. Modern epidemiology. 2nd ed. New York: Lippincott, Williams & Wilkins Publishers; 1998.
- 11. Census of India 2011 New Delhi: The Registrar General & Census Commissioner.; 2011 [cited 2014 15 January]. Available from: http://censusindia.gov.in/.
- 12. Broor S, Parveen S, Bharaj P, Prasad VS, Srinivasulu KN, Sumanth KM, et al. A prospective three-year cohort study of the epidemiology and virology of acute respiratory infections of children in rural India. PloS one. 2007;2(6):e491. Epub 2007/06/07. doi: 10.1371/journal.pone.0000491 pmid:17551572; PubMed Central PMCID: PMC1876256.
- 13. Gladstone BP, Das AR, Rehman AM, Jaffar S, Estes MK, Muliyil J, et al. Burden of illness in the first 3 years of life in an Indian slum. Journal of tropical pediatrics. 2010;56(4):221–6. Epub 2009/12/24. doi: 10.1093/tropej/fmp116 pmid:20028725; PubMed Central PMCID: PMC3693507.
- 14. Gupta M, Kumar R, Deb AK, Bhattacharya SK, Bose A, John J, et al. Multi-center surveillance for pneumonia & meningitis among children (<2 yr) for Hib vaccine probe trial preparation in India. The Indian journal of medical research. 2010;131:649–58. Epub 2010/06/03. pmid:20516536.
- 15. Russel F, Sanderson C, Temple B, K. M. Global review of the distribution of pneumococcal disease by age and region. World Health Organization, 2011.
- 16. Invasive Bacterial Infection Surveillance (IBIS) Group, (INCLEN) ICEN. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance Group. Lancet. 1999;353(9160):1216–21. Epub 1999/04/27. pmid:10217081. doi: 10.1016/0895-4356(96)89237-7
- 17. District Level Household and Facility Survey (DLHS-3), 2007–08: India. Mumbai: International Institute for Population Sciences (IIPS), 2010.
- 18. National Family Health Survey (NFHS-3), 2005–06: India. Mumbai: International Institute for Population Sciences (IIPS) and Macro International., 2007.
- 19. Broor S, Pandey RM, Ghosh M, Maitreyi RS, Lodha R, Singhal T, et al. Risk factors for severe acute lower respiratory tract infection in under-five children. Indian pediatrics. 2001;38(12):1361–9. Epub 2001/12/26. pmid:11752733.
- 20. Mathew JL, Patwari AK, Gupta P, Shah D, Gera T, Gogia S, et al. Acute respiratory infection and pneumonia in India: a systematic review of literature for advocacy and action: UNICEF-PHFI series on newborn and child health, India. Indian pediatrics. 2011;48(3):191–218. Epub 2011/04/12. pmid:21478555. doi: 10.1007/s13312-011-0051-8
- 21. Lucero MG, Nohynek H, Williams G, Tallo V, Simoes EA, Lupisan S, et al. Efficacy of an 11-valent pneumococcal conjugate vaccine against radiologically confirmed pneumonia among children less than 2 years of age in the Philippines: a randomized, double-blind, placebo-controlled trial. The Pediatric infectious disease journal. 2009;28(6):455–62. Epub 2009/06/02. doi: 10.1097/INF.0b013e31819637af pmid:19483514.
- 22. Manoharan A. Surveillance of invasive disease caused by Streptococus pneumonia or Haemophilius influenzae or Neisseria meningitidis in children (<5 years) in India. ESPID 2013; Milan2013.
- 23. Klugman KP, Madhi SA, Huebner RE, Kohberger R, Mbelle N, Pierce N, et al. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. The New England journal of medicine. 2003;349(14):1341–8. Epub 2003/10/03. doi: 10.1056/NEJMoa035060 pmid:14523142.
- 24. Prospective multicentre hospital surveillance of Streptococcus pneumoniae disease in India. Invasive Bacterial Infection Surveillance (IBIS) Group, International Clinical Epidemiology Network (INCLEN). Lancet. 1999;353(9160):1216–21. Epub 1999/04/27. pmid:10217081. doi: 10.1016/s0140-6736(98)07228-6
- 25. Brooks W, Breiman R, Goswami D. Invasive pneumococcal disease burden and implications for vaccine policy in urban Bangladesh. Am J Trop Med Hyg 2007;77:795–801. pmid:17984328
- 26. Kumar C, Singh PK, Rai RK. Coverage gap in maternal and child health services in India: assessing trends and regional deprivation during 1992–2006. Journal of public health. 2013;35(4):598–606. Epub 2013/01/30. doi: 10.1093/pubmed/fds108 pmid:23359666.
- 27. Gupta M, Kumar R, Deb AK, Bhattacharya SK, Bose A, John J, et al. Multi-center surveillance for pneumonia & meningitis among children (<2 yr) for Hib vaccine probe trial preparation in India. The Indian journal of medical research. 2010;131:649–58. Epub 2010/06/03. pmid:20516536.
- 28. Kumar S, Das BK, Kapil A. Streptococcus pneumoniae isolation form upper respiratory tract of children in rural community of North india. Pneumonia. 2014;3:36. doi: 10.1186/2047-2994-3-36. pmid:25671097
- 29. Rudan I, Boschi–Pinto C, Biloglav Z, Mulholland K, H. C. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ. 2008;(86):408–16. pmid:18545744 doi: 10.2471/blt.07.048769
- 30. Zodpey S, Hasan H, Chokshi M. Pediatrician’s perspective on Pneumococcal Conjugate Vaccines: An exploratory study in private sector. Indian Journal of Public Health. 2015;(in press). doi: 10.1016/j.jval.2014.08.2564
- 31. Madsen HO, Hanehoj M, Das AR, Moses PD, Rose W, Puliyel M, et al. Costing of severe pneumonia in hospitalized infants and children aged 2–36 months, at a secondary and tertiary level hospital of a not-for-profit organization. Tropical medicine & international health: TM & IH. 2009;14(10):1315–22. Epub 2009/09/02. doi: 10.1111/j.1365-3156.2009.02374.x pmid:19719464.